Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04205630 · ClinicalTrials.gov registry record · Phase 2
SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma
A Phase 2 study of Endometrial Cancer, sponsored by Byondis B.V..
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 20
- Study locations
NCT04205630: Completed Phase 2 study of Endometrial Cancer, sponsored by Byondis B.V..
NCT04205630 is a Phase 2 study of Endometrial Cancer that has completed, run by Byondis B.V.. The registered enrollment target is 64 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04205630, a Phase 2 study of Endometrial Cancer, has completed, sponsored by Byondis B.V..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of SYD985 in recurrent, advanced or metastatic endometrial cancer.
Primary Outcome
ORR is defined as the proportion of patients with an assessed best overall response of complete response or partial response according to Response Evaluation Criteria In Solid Tumors (RECIST) v1.1.
Conditions Studied
Interventions
- DRUG SYD985
Study Locations (20)
Other
- MedTrials - Krakow
- St. John of Dukla Oncology Center of Lublin Land - Lublin
- Arkhangelsk Clinical Oncology Center - Arkhangelsk
- Chelyabinsk Regional Clinical Oncology and Nuclear Medicine Center - Chelyabinsk
- Regional Oncology Center - Irkutsk
- Clinical Oncology Center - Omsk
- Orenburg Regional Clinical Oncology Center - Orenburg
- Oncology Center of Moskovskiy District - Saint Petersburg
- Private Medical Institution "EVROMEDSERVIS" - Saint Petersburg
- AV Medical Group - Saint Petersburg
- Oncology Center #2 - Sochi
- Tambov Regional Oncological Clinical Center - Tambov
- Republican Clinical Oncology Center - Ufa
- Volgograd Regional Clinical Oncology Center - Volgograd
- National Cancer Research Center - Belgrade
- Oncology Institute of Vojvodina (IOV), Clinic of Surgical Oncology, Department of Gynecology - Kamenitz
- Clinical Center Nis, Clinic of Oncology - Niš
- National University Hospital, Department of Hematology-Oncology - Singapore
- National Cancer Centre Singapore - Singapore
Connecticut
- Smilow Cancer Hospital (Yale) - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2020-05-28 |
| Est. Completion | 2023-04-25 |
| Phase | Phase 2 |
What the finished NCT04205630 record still lists
NCT04205630 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 1 intervention - of which SYD985 is the first listed.
NCT04205630 names 20 study sites across 2 states, led by Other, Connecticut.
Frequently Asked Questions
What is clinical trial NCT04205630 about?
NCT04205630 is a clinical study titled "SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma". The purpose of this study is to evaluate the safety and efficacy of SYD985 in recurrent, advanced or metastatic endometrial cancer.
What is the current status of trial NCT04205630?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2020-05-28. Estimated completion is 2023-04-25.
What conditions does trial NCT04205630 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT04205630?
The interventions under investigation include: SYD985 (DRUG).
Who is sponsoring clinical trial NCT04205630?
This trial is sponsored by Byondis B.V., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04205630 being conducted?
This trial has 20 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04205630's enrollment target sits among peer trials
64 113th of 181 higher than 69 of 181 other Endometrial Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
RECRUITING · Phase 2
-
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
RECRUITING · Phase 2
-
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RECRUITING · Phase 2
-
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI